Bright Minds Biosciences Inc. (DRUG) shares rallied Tuesday after the biotech company released compelling Phase 2 trial results for BMB-101, its experimental treatment for drug-resistant epilepsy. The data showed the drug substantially reduced seizures in two difficult-to-treat patient populations while maintaining a clean safety profile.

The BREAKTHROUGH trial tested BMB-101 in patients with Absence Seizures and Developmental and Epileptic Encephalopathies (DEE). DEE represents a particularly severe category of brain disorders where frequent, treatment-resistant seizures actively interfere with development, causing children to lose or fail to gain skills like sitting and talking. These conditions typically have genetic origins and present clinicians with limited treatment options.

The Numbers Tell a Strong Story

In the absence seizure cohort of 11 patients, BMB-101 delivered a 73.1% median reduction in seizures lasting three seconds or longer (p = 0.012 using the Wilcoxon Signed Rank Test). The drug also cut total time spent seizing by 74.4% over a 24-hour period, a measure researchers call "seizure burden" (p = 0.012). Patients showed robust reductions regardless of how long individual seizures lasted.

The DEE cohort, which included six patients, saw a 63.3% median reduction in major motor seizures. Breaking it down further, patients with Lennox-Gastaut Syndrome experienced a 60.3% reduction, while other DEE patients achieved an even more impressive 76.1% reduction.

Safety Profile Looks Clean

BMB-101 was generally well tolerated across the trial. The vast majority of treatment-emergent adverse events were mild (79.6%) or moderate (17.2%), and crucially, there were no serious adverse events related to the treatment itself. For a drug targeting vulnerable patient populations, that's exactly what you want to see.

An Unexpected Sleep Bonus

Here's where things get interesting. The trial also examined BMB-101's effects on sleep architecture, and patients experienced a 90% increase in REM sleep duration, jumping from 56.2 minutes at baseline to 106.7 minutes while on treatment. Total sleep time stayed roughly the same (9.1 hours versus 8.9 hours), meaning the drug improved sleep quality rather than just making people sleep more.

The company emphasized Tuesday that REM sleep plays a critical role in memory consolidation, emotional and behavioral regulation, and cognitive function. For patients already struggling with developmental challenges, better REM sleep could translate into meaningful quality-of-life improvements beyond seizure control.

What Comes Next

Bright Minds Biosciences has started preparing for global registrational trials in both Absence Seizures and DEE. The company plans to present additional data throughout the year, including long-term outcome information. They're also gearing up to launch a study in Prader-Willi Syndrome, currently expected to kick off in the first quarter of 2026.

DRUG shares closed up 22.23% at $97.80 on Tuesday following the announcement.